Epclusa(Sofosbuvir and Velpatasvir Tablets‌)

Sofosbuvir/Velpatasvir (Sofosbuvir/Velpatasvir, commonly known as "Sofosbuvir/Velpatasvir Combination Tablets") produced by Lucius Pharmaceuticals is a pan-genotypic hepatitis C treatment drug. It features high cure rate, relatively fixed treatment course and good overall tolerability, providing patients with a convenient and effective treatment option.

Overview of Key Usage Information for Sofosbuvir/Velpatasvir.

Active Ingredients

This product is a fixed-dose combination preparation, with the main active ingredients being sofosbuvir and velpatasvir.

Target Population

It is indicated for patients aged 3 years and older with chronic hepatitis C (HCV) infection.

Dosage and Administration

Adults: Take 1 tablet orally once daily.

Pediatric patients: Select tablets or oral granules of the corresponding strength based on body weight.

Use in Special Populations

Elderly patients and patients with mild to moderate hepatic or renal impairment: Generally, no dosage adjustment is required.

Pregnant and lactating women: The use of this drug requires careful evaluation by a healthcare provider.

Overdosage

In case of overdosage, seek medical attention immediately and receive symptomatic and supportive treatment.

Storage

Store the drug in a sealed container at a temperature below 30°C.

Pharmacokinetics

Sofosbuvir and velpatasvir are well absorbed after oral administration, with clear in vivo metabolic pathways. Attention should be paid to potential drug-drug interactions.

FDA，2022.04